Myungmoon Phar (017180) - Total Liabilities

Latest as of December 2025: ₩168.00 Billion KRW ≈ $113.85 Million USD

Based on the latest financial reports, Myungmoon Phar (017180) has total liabilities worth ₩168.00 Billion KRW (≈ $113.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Myungmoon Phar - Total Liabilities Trend (2009–2025)

This chart illustrates how Myungmoon Phar's total liabilities have evolved over time, based on quarterly financial data. See Myungmoon Phar working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Myungmoon Phar Competitors by Total Liabilities

The table below lists competitors of Myungmoon Phar ranked by their total liabilities.

Company Country Total Liabilities
K2A Knaust & Andersson Fastigheter AB (publ)
ST:K2A-B
Sweden Skr5.32 Billion
Chin Yang Chem
KO:051630
Korea ₩42.53 Billion
PJP Makrum S.A.
WAR:PJP
Poland zł442.09 Million
Gurktaler AG ST
VI:GAGS
Austria €568.00K
Dongil Technology Ltd
KQ:032960
Korea ₩3.59 Billion
Sapmer
PA:ALMER
France €75.71 Million
Tubos Reunidos S.A
MC:TRG
Spain €447.35 Million
Powercom Co Ltd
TW:3043
Taiwan NT$1.07 Billion

Liability Composition Analysis (2009–2025)

This chart breaks down Myungmoon Phar's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Myungmoon Phar market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.96 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.70 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.62 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Myungmoon Phar's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Myungmoon Phar (2009–2025)

The table below shows the annual total liabilities of Myungmoon Phar from 2009 to 2025.

Year Total Liabilities Change
2025-12-31 ₩168.00 Billion
≈ $113.85 Million
+8.48%
2024-12-31 ₩154.87 Billion
≈ $104.95 Million
+4.78%
2023-12-31 ₩147.79 Billion
≈ $100.16 Million
+9.33%
2022-12-31 ₩135.18 Billion
≈ $91.61 Million
-1.18%
2021-12-31 ₩136.80 Billion
≈ $92.71 Million
-10.15%
2020-12-31 ₩152.25 Billion
≈ $103.18 Million
-17.37%
2019-12-31 ₩184.25 Billion
≈ $124.86 Million
+22.83%
2018-12-31 ₩150.00 Billion
≈ $101.65 Million
+12.48%
2017-12-31 ₩133.36 Billion
≈ $90.37 Million
+5.51%
2016-12-31 ₩126.40 Billion
≈ $85.66 Million
-4.46%
2015-12-31 ₩132.30 Billion
≈ $89.66 Million
+12.59%
2014-12-31 ₩117.51 Billion
≈ $79.63 Million
-1.43%
2013-12-31 ₩119.21 Billion
≈ $80.79 Million
+3.24%
2012-12-31 ₩115.47 Billion
≈ $78.25 Million
-3.27%
2011-12-31 ₩119.37 Billion
≈ $80.90 Million
+23.03%
2010-12-31 ₩97.02 Billion
≈ $65.75 Million
+7.78%
2009-12-31 ₩90.02 Billion
≈ $61.01 Million
--

About Myungmoon Phar

KO:017180 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$29.29 Million
₩43.22 Billion KRW
Market Cap Rank
#23893 Global
#1639 in Korea
Share Price
₩1273.00
Change (1 day)
-3.56%
52-Week Range
₩1267.00 - ₩1945.00
All Time High
₩10277.86
About

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more